Abstract
Monitoring biomarkers offers more reliable results, compared to typical mycotoxin exposure estimation approaches that employ their prevalence in food in combination with population food intake data. Free forms of fumonisins B1 and B2 (FB1+ FB2), and free zearalenone (ZEN) together with three of its enteric metabolites have been identified as fitting indicators for exposures to the parent mycotoxins. This study investigated the similarities in regional and age-related mycotoxin exposures among sampled females employed in the cereal value chain in Ghana. After obtaining ethical clearance to conduct the study, spot urine samples were collected from females in cereal growing communities in The Upper West, Northern, Ashanti and Greater Accra regions of Ghana. The collected bio-samples were processed appropriately and LC-MS/MS chromatographic methods used to determine the presence and levels of FB1, FB2, ZEN, α-ZEL, β-ZEL and ZEN-14, glucuronide. The results indicate that while probable daily intake of the mycotoxins decreased with age, being higher for the 10-19 age groups, exposures were higher in the 55+ age group, consistent with age-related accumulation. The creatinine adjusted mycotoxin levels also presented a snapshot of renal function across the four regions being generally homogenous for participants in the Ashanti region. Wide variations in creatinine concentrations were observed for the Upper West and Northern regions and the spread was heterogenous for Greater Accra. The insight into age-related mycotoxin exposures agrees with previous findings of significant links between FB1 exposures and adverse health outcomes. ZEN exposures were higher in the 10-19 age group suggesting the potential for younger age groups to face significant risks due to exposure to the mycotoxin. The findings from this biomonitoring exercise prompts heightened public health interventions, guided by strategies that will adequately address the age-related risk of mycotoxin exposures in different populations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical clearance for this study was sought from the Committee on Human Research and Publication Ethics (CHRPE), Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana. The clearance is registered under CHRPE/AP/245/21. A copy of the ethical clearance has been attached.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All the relevant data are within the manuscript and its Supporting Information files. A URL is also provided to easily access the Supporting Information files.
